Metabolic Disorders
Tibolone reduces fracture risk in osteoporotic women but increases stroke risk
N Engl J Med. 2008 Aug 14;359(7):697-7084538 post-menopausal women (age 60-85) with low bone mineral density were randomized to either receive a daily dose of Tibolone (1.25mg) or an identical placebo. The results indicated that the use of tibolone resulted in a reduced risk for developing vertebral and non-vertebral fractures, invasive breast cancer as well as colon cancer. However, it is important to note that tibolone did increase the risk for stroke, and therefore should not be used as treatment in elderly women with other risk factors for stroke.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
